Sund Capital aimed high when the investment fund, led by former Zealand Pharma CEO David Solomon, announced its ambition of raising up to DKK 2 billion for investing in promising biotech companies. Now, the fund is shutting down.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.